

²⁷**Abstract**

²⁸**Objectives**

²⁹To triage patients with a high likelihood of osteopenia before referring them for a standard bone

30 mass density test for diagnosis.

³¹**Introduction**

32 Osteopenia defined by low bone mineral density, is a precursor for osteoporosis and is primarily 33 associated with aging-linked natural bone loss in adulthood. The model and findings can be 34 used to adopt an inclusive screening and swift treatment model that can work in most settings 35 where resources are limited.

³⁶**Methods**

³⁷We developed a diagnostic prediction rule based on clinical characteristics. A retrospective 38 cohort of 798 patients who were going to be diagnosed with osteopenia or osteoporosis, within 39 January-September 2022. The multivariable logistic regression to assess potential predictors. ⁴⁰The logistic coefficients were transformed as a risk-based scoring system. The internally 41 validation was performed using a bootstrapping procedure.

⁴²**Results**

⁴³The model initially included seven predictors: sex, age, height, weight, body mass index, 44 diabetes mellitus, and estimated glomerular filtration rate. However, after using backward 45 elimination for model reduction, only three predictors—sex, age, and weight—were retained in ⁴⁶the final model. The discrimination performance was assessed with the area under the receiver 47 operating characteristic curve (AuROC); it was 0.779 (95%CI 0.74-0.82), and the calibration plot

48 showed good calibration. For internal validation, bootstrap resampling was utilized, yielding an 49 AuROC of 0.768 (95% CI 0.73-0.81), indicating robust performance of the model. ⁵⁰**Conclusions**

51 This study developed and internally validated the Osteopenia Simple Scoring System. This 52 clinical risk score could be one of the important tools for diagnosing osteopenia and allocating 53 resources in resource-limited settings.

54

⁵⁵**Keywords**

56 Osteopenia, Osteoporosis, Risk prediction, Diagnostic prediction rule, Clinical prediction

57

⁵⁸**Introduction**

59 **Steopenia is a decrease in bone mineral density (BMD) below normal values for their** 60 ages, is the initial stage of bone loss, which may progress to a more severe condition i.e. 61 osteoporosis. However, that doesn't always lead to osteoporosis depending on many factors. ⁶²The primary cause of osteopenia is the natural bone loss that occurs gradually during 63 adulthood. Secondary causes supposed to accelerate bone loss include lifestyle factors[1] such 64 as smoking, certain underlying diseases, steroid usage, early menopausal woman, rheumatoid ⁶⁵arthritis, and some medications as well. Osteopenia is often a precursor to osteoporosis, which 66 are now diagnosed by measuring bone mineral density using dual energy X-ray absorptiometry 67 bone scans. [2] The osteopenia, as defined by the World Health Organization (WHO) is a t-score 68 between -1 to -2.5, while values less than -2.5 are diagnostic for osteoporosis.[3, 4] Osteopenia

⁶⁹is not considered a disease while osteoporosis is. In the other hand, osteopenia is considered a 70 marker for risk of fractures.[5]

71 The potential predictors of bone mass density in patients with fractures treated in 72 hospitals were found that factors such as age, sex, smoking, history of adult wrist fractures, 73 spinal deformities[6, 7], history of adult hip fractures, and osteoarthritis of the spine[8] 74 significantly differed statistically between groups with normal bone mass density and those with 75 bone mass density below -1 standard deviation. Low body mass index, low vitamin D level[9] 76 and diabetes[10, 11], chronic kidney disease[12] are also associated with osteoporosis.

77 There has been increasing attention to the clinical predictive models of diagnostic 78 screening models for the prediction of fracture risk in patients diagnosed with osteoporosis.[13-⁷⁹16] Clinical predictive models are commonly used in clinics for the purpose of disease 80 diagnosis, outcome prediction, and evaluation of the clinical response.[17, 18] We used 81 multivariable logistic regression to develop predictive models for possible use in the facilitation 82 of early treatment and screening for osteopenia.

83 In countries with limited resources, access to a test for bone mass density would be far-84 fetched. This research aims to help triage patients at high risk of having osteopenia before they 85 are referred for a standard BMD test for diagnosis. This work could be extended to programs 86 aimed to osteopenia or osteoporosis screening in the community.

87

88

89

90

⁹¹**Methods**

⁹²**Study design and setting**

93 This diagnostic prediction research, utilizing a retrospective cohort design, was 94 conducted at Suranaree University of Technology Hospital in Nakhon Ratchasima, located in the 95 Iower northeastern region of Thailand. Our university hospital conducts more than 2,000 bone 96 mass density tests annually.

97 This study retrospectively collected demographic and laboratory data from the electronic 98 medical records of Suranaree University Technology Hospital. The data included age, weight, ⁹⁹height, body mass index, smoking status, early menopause, rheumatoid arthritis, diabetes ¹⁰⁰mellitus, chronic kidney disease, serum creatinine levels, and estimated glomerular filtration 101 rates. Patient data were accessed for research purposes between April 4th and 12th 2024. 102 Patients who visited the hospital from January to September 2022 and were intended to be 103 diagnosed with osteopenia or osteoporosis were assessed for eligibility. Patients with a previous 104 diagnosis of osteopenia or osteoporosis were excluded from the study.

105

¹⁰⁶**Confirmation of cases**

107 All patients included in this study underwent a BMD test on a single machine at the 108 hospital's checkup center. In this study, osteopenia is defined as a T-score of less than -1, and 109 osteoporosis is defined as a T-score of less than -2.5.

110

¹¹¹**Statistical analysis and sample size calculations**

112 Continuous variables were assessed for normality and presented as means and 113 standard deviations if normally distributed, or medians and interquartile ranges if not. Mean

114 differences of the variables between the two groups were compared by using an independent t-115 test, or rank-sum test based on the distribution of the data. Categorical data were expressed as 116 frequencies and percentages of the total in each group and compared between groups using 117 either the exact probability test or chi-square test where applicable. We assessed diagnostic 118 performance and potential prediction by univariable logistic regression, using crude odds ratios ¹¹⁹(OR) and their corresponding area under the receiver operating characteristic curves (AuROC). 120 Statistically significant two-sided p-values less than 0.05 were considered in applicable cases. 121 All analyses were done using Stata statistical software version 17. In the development of clinical 122 prediction rules based on methods described by Riley et al.[19], it was estimated that the 123 minimum sample size for a multivariable prediction model with a binary outcome was required. ¹²⁴This was estimated from a model c-statistic of 0.8, six candidate predictors, and an assumed 125 prevalence of osteopenia from a preliminary study, standing at 46%, to get the minimum sample 126 size of 382 cases with 176 events.

127

¹²⁸**Model development and validation**

129 All potential predictor variables necessary for diagnostic prediction of osteopenia in our 130 routine practice were extracted from the hospital's electronic medical records. These included 131 age, sex, height, weight, smoking status, serum creatinine levels, diabetes mellitus (with or 132 without insulin use), hypertension, early menopause, chronic kidney disease, steroid use, and 133 rheumatoid arthritis.

¹³⁴We identified potential predictors based on prior knowledge; about the biological 135 process, a review of the literature, and available prediction models. Subsequently, the 136 exploratory analysis of significant predictors was done using a univariable logistic regression. ¹³⁷We assessed the significance of the predictors through the diagnostic odds ratio and the

138 corresponding p-value. Additionally, we assessed the area under the receiver operating 139 characteristic curve (AuROC) for each univariable logistic model. Any predictor variable showing 140 an odds ratio >1.00, significant p-value of <0.05, and higher AuROC than others was included in 141 the model. Continuous potential variables were categorized into ordinal following the preceding 142 model and review of literature. Therefore, in this respect, understanding the nature of the 143 relationship between the dependent variable and the outcome to determines the cut-off point.

144 The model to be used for the study is derived from the multivariable logistic regression 145 with a binary outcome. The factors that not contributing to the outcome were removed using the 146 backward elimination method. A total of four predictors got pruned from the model: height, body ¹⁴⁷mass index, diabetes mellitus, and estimated glomerular filtration rate. Diagnostic performance 148 of the developed model was assessed using the reduced multivariable model by means of 149 calibration and discrimination. Calibration was assessed by the Hosmer-Lemeshow goodness-150 of-fit test, and a plot was applied to show both the model-estimated disease probabilities and 151 observed disease data. The discriminative ability of the model was graphically tested through a 152 distributional plot. It was reported with the area under the curve of the receiver operating 153 characteristic. The internal validation was conducted using the bootstrapping procedure of 1000 154 replications.

155

156

157

¹⁵⁸**Simplified score derivation**

¹⁵⁹Each predictor in the multivariable model was assigned a specific score based on the 160 logistic regression coefficients. The coefficient of each predictor was divided by the smallest

161 coefficient and then rounded up to the nearest whole number. Utilizing a population-analogue 162 approach, the positive predictive value (PPV) was calculated to demonstrate the predictive 163 performance. Calibration and discrimination measurements were also conducted using the 164 score-based multivariable logistic model.

165

¹⁶⁶**Ethical considerations**

167 This research was conducted based on ethical standards of clinical research. According 168 to the Helsinki Declaration and began its activity only after it received approval and permission 169 from the Institutional Review Board of Suranaree University of Technology regarding the review 170 of the research protocol. Retrospective data were extracted through data record forms. The 171 patients were treated by the routine hospital staff and were not affected by any research 172 protocols, the informed consent was waived. The study adhered to the reporting guidelines 173 outlined in the Transparent Reporting of a multivariable prediction model for Individual 174 Prognosis Or Diagnosis (TRIPOD) statement. The study protocol received approval from the 175 Institutional Review Board of Suranaree University of Technology, with approval number COA 176 No.32/2567.

- 177
- 178
- 179

¹⁸⁰**Results**

¹⁸¹**Participants**

182 A total of 798 participants were evaluated for osteopenia at the Suranaree University of 183 Technology check-up center from January to September 2022. After excluding 242 patients 184 previously diagnosed with osteopenia or osteoporosis, the remaining 556 patients were divided 185 into two groups: 230 in the osteopenia group and 326 in the non-osteopenia group. The 186 prevalence of osteopenia and osteoporosis was 41.4% and 5.4%, respectively. Of these, 198 187 patients in the osteopenia group and 188 in the non-osteopenia group were female. The mean 188 age for the osteopenia group was 65.07 ± 10.34 years, compared to 59.03 ± 9.14 years for the 189 non-osteopenia group. The average weight was 57.40 ± 9.58 kg for osteopenia cases and 190 57.40±12.71 kg for non-osteopenia cases. Average heights were 155.22±7.50 cm for the 191 osteopenia group and 160.53 ± 8.00 cm for the non-osteopenia group. The mean BMI was 192 24.68 ± 14.44 kg/m^o2 for osteopenia cases and 25.64 ± 4.02 kg/m^o2 for non-osteopenia cases ¹⁹³(Table 1). There were significant differences in groups in terms of female gender, age, weight, 194 height, BMI, and current underlying diseases, including diabetes mellitus, as well as in 195 laboratory factors such as estimated glomerular filtration rate (eGFR) ($p < 0.001$). There were 196 no significant differences in the serum creatinine, early menopause, rheumatoid arthritis, and 197 smoking status.

- 198
- 199
- 200
- 201

²⁰²**Model development and internal validation**

²⁰³The following continuous variables were converted to ordinal variables: eGFR, body ²⁰⁴mass index, weight, age, and height. The cut points were determined based on information

205 gathered from the literature and prior models. The model was developed using multivariable 206 logistic regression, which demonstrated the relevant characteristics included in the regression 207 for predicting osteopenia were female gender, age, height, weight, BMI, diabetes mellitus, and 208 eGFR. These factors remained significant in the multivariable logistic regression analysis and 209 were integrated into the full risk prediction model (Table 2).

210 The reduced model employed a backward elimination strategy. Multivariable logistic 211 regression indicated that female gender, age, and weight, which were included in the final 212 model, were found to be statistically significant. The scoring ranged from 1 to a maximum of 5 213 points, accumulating to a total of 13 points, summing up to 133. Ages over 70 years were 214 assigned the highest scores (Table 3).

215 The calibration plot of the estimated risk of osteopenia compared to the actual risk 216 showed acceptable calibration, with observed probabilities closely matching the expected 217 probabilities and exhibiting minimum variation from the ideal (Figure 2). The Hosmer-Lemeshow 218 goodness-of-fit statistic yielded a non-significant result for the outcome ($p = 0.614$), suggesting 219 that the statistical fitness of the model was satisfactory, given that a p-value larger than 0.1 was 220 regarded indicative of a good fit. Area under the receiver operating characteristic curve ²²¹(AuROC) was 0.7792 (95% CI 0.74-0.82), showing a good performance in model discrimation ²²²(Figure 3).

223 The process of internal validation was conducted by utilizing a bootstrap resampling 224 technique with 1000 repeats. Following the adjustment for optimism in discrimination, the 225 bootstrap analysis produced an area under the receiver operating characteristic curve (AuROC) 226 of 0.768 (95% CI 0.73-0.81), indicates a good ability and a significant level of agreement 227 between the estimated and observed probabilities of risk (Supplementary material).

228

²²⁹**Simple score cut point identification**

230 A very high sensitivity of 94.8% (95% CI 91.1-97.3) was observed at a cut point of ≥4, 231 while the specificity was 28.5% (95% CI 23.7-33.8). At a score of ≥10, the specificity was high at ²³²91.7% (95% CI 88.2-94.5), but the sensitivity was lower at 44.3% (95% CI 37.8-51.0). The best 233 cut point was determined by achieving a balance between sensitivity and specificity. For a score 234 of 6 or above, the sensitivity was 82.2% (95% CI 76.6-86.9), and the specificity was 55.2% ²³⁵(95% CI 49.6-60.7), with a likelihood ratio of positive result of 1.83 (95% CI 1.60-2.10). The 236 positive predictive value was 56.4% (95% CI 50.9-61.8), whereas the negative predictive value 237 was 81.4% (95% CI 75.7-86.3) (Table 4).

238

²³⁹**Clinical utility**

240 In the context of triaging patients for osteopenia, the newly developed diagnostic 241 prediction rule was applied. 32.37% (180 patients out of 556) were true negatives, this model 242 can reduce the unnecessary BMD tests. Among the 211 patients who scored negatively (simple 243 score below 6), 41 patients (18.55%) were false negatives for osteopenia, and only 2 patients ²⁴⁴(0.36% of all patients) were diagnosed with osteoporosis. On the other hand, among those with 245 a positive score test (simple score above 6), 146 patients had normal BMD and were 246 recommended for follow-up, while 189 patients were confirmed to have osteopenia and received 247 medical treatment according to the treatment guidelines.

²⁴⁸**Discussion**

249 Despite the limitations, the current study managed to establish a diagnostic rule for 250 predicting patients with osteopenia, which could strengthen an early diagnosis and the 251 treatment of patients in osteopenia. This finding is highly relevant because our hospital faces a

252 significant burden of bone density testing and a high prevalence of osteopenia. Moreover, the 253 application of a predictive diagnosis logistic regression model, as conducted in the current 254 study, also supports the efforts of other studies to implement more predictive analytics in clinical 255 settings[20].

256 Our results emphasize the importance of a multi-factor approach in novel predictive ²⁵⁷model formulation. Specifically, our model uses the same age, sex, and weight as the known 258 risk factors, established to predict osteopenia and osteoporosis, proven to be significant in other 259 studies.[21] Similarly, the use of backward elimination for the purpose of precise identification of 260 the factors allowed reducing the insignificant height and BMI from the model, as these variables 261 have negligible impact on the model's predictability of outcomes in our patients.[22]

262 The calibration and discrimination results of our model are satisfactory and being 263 confirmed. The results of the Hosmer-Lemeshow test and AuROC testify to the model's effective 264 prediction of true osteopenia cases. This is confirmed by the literature on the appropriateness of 265 calculating these metrics to check how well a diagnostic tool performs in clinical epidemiology 266 and diagnostics.[23]

267 Furthermore, the use of this model demonstrated its significant clinical use. The 268 prioritization of resources based on a simple score, which identifies high and low-risk patients, 269 may also lower the risk of untreated osteopenia transitioning to osteoporosis and adhere to 270 WHO, who suggests that more tests should be conducted on populations at higher risks.[24, 25]

271 Although the FRAX score is currently used in predicting the 10-year probability of hip 272 fracture[26, 27], a study by Teeratakulpisarn et al[28]. reports that even though there is 273 concordance between the 10-year probability of hip fractures for FRAX scores with and without 274 BMD, this concordance declines in elderly and osteoporotic participants, and in those with

275 FRAX scores without BMD. Therefore, to achieve higher accuracy, it is advisable to undergo 276 BMD testing.

277 **In 2001, Koh LK et al.** [29] designed a simple tool to categorize postmenopausal Asian 278 women (OSTA score). They utilized a questionnaire to identify those in the cohort with 279 osteoporosis, defined as BMD T-scores \leq -2.5 and use multivariable logistic regression analysis. 280 The tool had a good performance with an area under the ROC curve of 0.79. Subsequently, it 281 showed sensitivity of 91%, specificity of 45%, among others.[29] Additionally, upon a validation 282 in Thai population, OSTA score presented sensitivity of 51.7% and specificity of 77.4% with a 283 false negative rate of \sim 20%. [30-33] The OSTA risk classification system showed that high and 284 medium-risk patients were significantly more likely to sustain injuries in falls and have different 285 femoral bone fractures patterns compared to low-risk patients. Machine learning models 286 particularly artificial neural networks offer another opportunity to predict low BMD. Comparison 287 of both ANN models to logistic regression models to predict low BMD had no significantly 288 different in performance for either the femoral neck or lumbar spine.[34] Although the OSTA 289 score performs well within the Thai population and particularly among postmenopausal women, 290 however, it can be limited use to the general population.

291 Cur model's stability and reliability were internal validation via bootstrapping, process 292 accounting for the potential optimism that can compromise prediction models developed in 293 narrow or specific populations. All of these methods make our research more reliable and can 294 be used to apply to similar settings with limited health care resources.

295 The study also has its limitations. In particular, the specificity of the model at some cut 296 points was insufficient for real-life applications, resulting in overdiagnosis and overtreatment. 297 This compromise between sensitivity and specificity is common in the development of 298 diagnostic instruments, and it needs to be adjusted depending on the costs and risks of the

- 299 disease. For future research, it is possible not only to include new, more prognostic factors but
- 300 also to progress statistical instruments, such as machine learning. Further external validation is
- 301 also required before adopting this model in other settings.
- 302

³⁰³**Conclusion**

³⁰⁴The development of a diagnostic prediction rule for osteopenia in a resource-limited 305 context is a major progress in the field of bone health management. This instrument is likely to 306 enhance patient prognosis and maximize the use of available healthcare resources by detecting 307 and offering timely therapeutic treatment to those at risk.

308

³⁰⁹**Acknowledgement**

310 This paper was supported by Suranaree University of Technology.

311

³¹²**Funding**

313 None

³¹⁴**Conflict of interest**

315 None

316

³¹⁷**Author contribution statement**

- 318 NK and TJ contributed to all parts of the research.PT, KP, and PT focused on discussing,
- 319 reviewing, and editing the manuscript.
- 320

³²¹**Figure legends**

- ³²²**Figure 1:** Study flow.
- ³²³**Figure 2:** Calibration plot for model predicted risk for osteopenia versus actual risk.
- ³²⁴**Figure 3:** Discrimination performance of the newly developed model, using clinical
- 325 characteristics to classify patients with normal and low bone mass density.
- ³²⁶**Figure 4:** Clinical utility.
- 327
- 328
-
- 329
- 330
- 331

³³²**Tables**

- ³³³**Table 1:** Baseline patient characteristics, underlying diseases, and laboratory investigations of
- 334 the derivation cohort, along with a comparison of osteopenia cases and normal bone mineral
- 335 density tests ($n = 556$).

336 Abbreviations: eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval

337

338

339

340

341

³⁴²**Table 2:** Full model multivariable logistic regression analysis.

343 Abbreviation: mOR, multivariable odds ratio; BMI, body mass index; GFR, glomerular filtration

344 rate

345

346

- 347
-
- 348
- 349
- 350

351

³⁵²**Table 3:** Reduced model with logit coefficients.

³⁵³Abbreviation: mOR, multivariable odds ratio; BMI, body mass index

354

- ³⁵⁵**Table 4:** Selection of score cut-off point with sensitivity, specificity, LHR+, PPV, NPV, and along
- 356 with 95% confidence interval.

357 Abbreviation: LHR+, likelihood ratio for positive test; PPV, positive predictive value; NPV,

358 negative predictive value

359

360

- 361
-
- 362
-
- 363

364

³⁶⁵**References**

366 1. Rychter AM, Ratajczak AE, Szymczak-Tomczak A, Michalak M, Eder P, Dobrowolska A,
367 et al. Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with 367 et al. Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with 368 Inflammatory Bowel Disease. Nutrients. 2021:13(6). Epub 2021/06/03. doi:

- 368 Inflammatory Bowel Disease. Nutrients. 2021;13(6). Epub 2021/06/03. doi:
369 10.3390/nu13061863. PubMed PMID: 34070791; PubMed Central PMCID: 369 10.3390/nu13061863. PubMed PMID: 34070791; PubMed Central PMCID: PMCPMC8227497.
370 2. Blake GM. Fogelman I. The role of DXA bone density scans in the diagnosis and
- 370 2. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and
371 treatment of osteoporosis. Postgrad Med J. 2007:83(982):509-17. Epub 2007/08/07. doi:
- 371 treatment of osteoporosis. Postgrad Med J. 2007;83(982):509-17. Epub 2007/08/07. doi:
372 10.1136/pgmi.2007.057505. PubMed PMID: 17675543; PubMed Central PMCID:
- ³⁷²10.1136/pgmj.2007.057505. PubMed PMID: 17675543; PubMed Central PMCID:

- 376 PMID: 28293453; PubMed Central PMCID: PMCPMC5335887.
377 4. Johnell O, Kanis J. Epidemiology of osteoporotic fracture 377 4. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16
378 Suppl 2:S3-7. Epub 2004/09/15. doi: 10.1007/s00198-004-1702-6. PubMed PMID: 1536569
- ³⁷⁸Suppl 2:S3-7. Epub 2004/09/15. doi: 10.1007/s00198-004-1702-6. PubMed PMID: 15365697.

³⁷³ PMCPMC2600106.
374 3. Sözen T, Öz

^{374 3.} Sözen T, Özışık L, Başaran N. An overview and management of osteoporosis. Eur J
375 Rheumatol. 2017;4(1):46-56. Epub 2017/03/16. doi: 10.5152/eurirheum.2016.048. PubMed 375 Rheumatol. 2017;4(1):46-56. Epub 2017/03/16. doi: 10.5152/eurjrheum.2016.048. PubMed
376 PMID: 28293453: PubMed Central PMCID: PMCPMC5335887.

379 5. Tran T, Bliuc D, Pham HM, van Geel T, Adachi JD, Berger C, et al. A Risk Assessment
380 Tool for Predicting Fragility Fractures and Mortality in the Elderly. J Bone Miner Res. 380 Tool for Predicting Fragility Fractures and Mortality in the Elderly. J Bone Miner Res.
381 2020;35(10):1923-34. Epub 2020/05/28. doi: 10.1002/jbmr.4100. PubMed PMID: 324 ³⁸¹2020;35(10):1923-34. Epub 2020/05/28. doi: 10.1002/jbmr.4100. PubMed PMID: 32460361. 382 6. Rozental TD, Shah J, Chacko AT, Zurakowski D. Prevalence and predictors of
383 osteoporosis risk in orthopaedic patients. Clin Orthop Relat Res. 2010;468(7):1765-72 383 osteoporosis risk in orthopaedic patients. Clin Orthop Relat Res. 2010;468(7):1765-72. Epub
384 2009/11/17. doi: 10.1007/s11999-009-1162-6. PubMed PMID: 19911243; PubMed Central ³⁸⁴2009/11/17. doi: 10.1007/s11999-009-1162-6. PubMed PMID: 19911243; PubMed Central 385 PMCID: PMCPMC2881983.
386 7. Lane NE. Epidemiolo 386 7. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol.
387 2006;194(2 Suppl): S3-11. Epub 2006/02/02. doi: 10.1016/j.ajog. 2005.08.047. PubMed PMID: 387 2006;194(2 Suppl):S3-11. Epub 2006/02/02. doi: 10.1016/j.ajog.2005.08.047. PubMed PMID:
388 16448873. 388 <mark>16448873.</mark>
389 8. Gra 389 8. Grams AE, Rehwald R, Bartsch A, Honold S, Freyschlag CF, Knoflach M, et al.
390 Correlation between degenerative spine disease and bone marrow density: a retrospec 390 Correlation between degenerative spine disease and bone marrow density: a retrospective
391 investigation. BMC Med Imaging. 2016;16:17. Epub 2016/02/26. doi: 10.1186/s12880-016-391 investigation. BMC Med Imaging. 2016;16:17. Epub 2016/02/26. doi: 10.1186/s12880-016-
392 0123-2. PubMed PMID: 26911278; PubMed Central PMCID: PMCPMC4765052. 392 0123-2. PubMed PMID: 26911278; PubMed Central PMCID: PMCPMC4765052.
393 9. Tang G. Feng L. Pei Y. Gu Z. Chen T. Feng Z. Low BMI. blood calcium an 393 9. Tang G, Feng L, Pei Y, Gu Z, Chen T, Feng Z. Low BMI, blood calcium and vitamin D, 394 kyphosis time, and outdoor activity time are independent risk factors for osteoporosis in 394 kyphosis time, and outdoor activity time are independent risk factors for osteoporosis in
395 postmenopausal women. Front Endocrinol (Lausanne). 2023:14:1154927. Epub 2023/11 395 postmenopausal women. Front Endocrinol (Lausanne). 2023;14:1154927. Epub 2023/11/08.
396 doi: 10.3389/fendo.2023.1154927. PubMed PMID: 37937050; PubMed Central PMCID: 396 doi: 10.3389/fendo.2023.1154927. PubMed PMID: 37937050; PubMed Central PMCID:
397 PMCPMC10627178. 397 PMCPMC10627178.
398 10. Tang Y, Zhang 398 10. Tang Y, Zhang L, Ye D, Zhao A, Liu Y, Zhang M. Causal relationship between Type 1
399 diabetes and osteoporosis and fracture occurrence: a two-sample Mendelian randomization 399 diabetes and osteoporosis and fracture occurrence: a two-sample Mendelian randomization
400 analysis. Osteoporos Int. 2023;34(6):1111-7. Epub 2023/04/04. doi: 10.1007/s00198-023-06 400 analysis. Osteoporos Int. 2023;34(6):1111-7. Epub 2023/04/04. doi: 10.1007/s00198-023-06734-
401 6. PubMed PMID: 37012460. 401 6. PubMed PMID: 37012460.
402 11. Ali D. Tencerova M. Fi 402 11. Ali D, Tencerova M, Figeac F, Kassem M, Jafari A. The pathophysiology of osteoporosis
403 in obesity and type 2 diabetes in aging women and men: The mechanisms and roles of 403 in obesity and type 2 diabetes in aging women and men: The mechanisms and roles of 404 increased bone marrow adiposity. Front Endocrinol (Lausanne). 2022;13:981487. Epub 404 increased bone marrow adiposity. Front Endocrinol (Lausanne). 2022;13:981487. Epub
405 2022/10/04. doi: 10.3389/fendo.2022.981487. PubMed PMID: 36187112; PubMed Centi 405 2022/10/04. doi: 10.3389/fendo.2022.981487. PubMed PMID: 36187112; PubMed Central
406 PMCID: PMCPMC9520254. 406 PMCID: PMCPMC9520254.
407 12. Hampson G, Elder G 407 12. Hampson G, Elder GJ, Cohen-Solal M, Abrahamsen B. A review and perspective on the
408 assessment, management and prevention of fragility fractures in patients with osteoporosis and 408 assessment, management and prevention of fragility fractures in patients with osteoporosis and
409 chronic kidney disease. Endocrine. 2021;73(3):509-29. Epub 2021/05/12. doi: 10.1007/s12020-409 chronic kidney disease. Endocrine. 2021;73(3):509-29. Epub 2021/05/12. doi: 10.1007/s12020-
410 021-02735-9. PubMed PMID: 33974225: PubMed Central PMCID: PMCPMC8325650. 410 021-02735-9. PubMed PMID: 33974225; PubMed Central PMCID: PMCPMC8325650.
411 13. Tan J, Zhang Z, He Y, Xu X, Yang Y, Xu Q, et al. Development and validation of 411 13. Tan J, Zhang Z, He Y, Xu X, Yang Y, Xu Q, et al. Development and validation of a risk
412 prediction model for osteoporosis in elderly patients with type 2 diabetes mellitus: a 412 prediction model for osteoporosis in elderly patients with type 2 diabetes mellitus: a
413 retrospective and multicenter study. BMC Geriatrics. 2023;23(1):698. doi: 10.1186/s 413 retrospective and multicenter study. BMC Geriatrics. 2023;23(1):698. doi: 10.1186/s12877-023-
414 04306-1. ⁴¹⁴04306-1. 415 14. Mauck KF, Cuddihy MT, Atkinson EJ, Melton LJ, 3rd. Use of clinical prediction rules in
416 detecting osteoporosis in a population-based sample of postmenopausal women. Arch Intern 416 detecting osteoporosis in a population-based sample of postmenopausal women. Arch Intern
417 Med. 2005:165(5):530-6. Epub 2005/03/16. doi: 10.1001/archinte.165.5.530. PubMed PMID: 417 Med. 2005;165(5):530-6. Epub 2005/03/16. doi: 10.1001/archinte.165.5.530. PubMed PMID:
418 15767529. ⁴¹⁸15767529. 419 15. Leeyaphan J, Rojjananukulpong K, Intarasompun P, Peerakul Y. Development and
420 Validation of a New Clinical Diagnostic Screening Model for Osteoporosis in Postmenopau 420 Validation of a New Clinical Diagnostic Screening Model for Osteoporosis in Postmenopausal
421 Vomen. J Bone Metab. 2023;30(2):179-88. Epub 2023/07/14. doi: 10.11005/jbm.2023.30.2.17 421 Women. J Bone Metab. 2023;30(2):179-88. Epub 2023/07/14. doi: 10.11005/jbm.2023.30.2.179.
422 PubMed PMID: 37449350; PubMed Central PMCID: PMCPMC10346005. 422 PubMed PMID: 37449350; PubMed Central PMCID: PMCPMC10346005.
423 16. Wang J, Kong C, Pan F, Lu S. Construction and Validation of a Nor 423 16. Wang J, Kong C, Pan F, Lu S. Construction and Validation of a Nomogram Clinical
424 Prediction Model for Predicting Osteoporosis in an Asymptomatic Elderly Population in Bei 424 Prediction Model for Predicting Osteoporosis in an Asymptomatic Elderly Population in Beijing. J
425 Clin Med. 2023;12(4). Epub 2023/02/26. doi: 10.3390/jcm12041292. PubMed PMID: 36835828; 425 Clin Med. 2023;12(4). Epub 2023/02/26. doi: 10.3390/jcm12041292. PubMed PMID: 36835828;
426 PubMed Central PMCID: PMCPMC9967366. 426 PubMed Central PMCID: PMCPMC9967366.
427 17. Aibar-Almazán A, Voltes-Martínez A, C 427 17. Aibar-Almazán A, Voltes-Martínez A, Castellote-Caballero Y, Afanador-Restrepo DF,
428 Carcelén-Fraile MDC, López-Ruiz E. Current Status of the Diagnosis and Management of Carcelén-Fraile MDC, López-Ruiz E. Current Status of the Diagnosis and Management of

429 Osteoporosis. Int J Mol Sci. 2022;23(16). Epub 2022/08/27. doi: 10.3390/ijms23169465.
430 PubMed PMID: 36012730; PubMed Central PMCID: PMCPMC9408932. 430 PubMed PMID: 36012730; PubMed Central PMCID: PMCPMC9408932.
431 18. Sun X, Chen Y, Gao Y, Zhang Z, Qin L, Song J, et al. Prediction M 431 18. Sun X, Chen Y, Gao Y, Zhang Z, Qin L, Song J, et al. Prediction Models for Osteoporotic
432 Fractures Risk: A Systematic Review and Critical Appraisal. Aging Dis. 2022;13(4):1215-38. 432 Fractures Risk: A Systematic Review and Critical Appraisal. Aging Dis. 2022;13(4):1215-38.
433 Epub 2022/07/21. doi: 10.14336/ad.2021.1206. PubMed PMID: 35855348; PubMed Central 433 Epub 2022/07/21. doi: 10.14336/ad.2021.1206. PubMed PMID: 35855348; PubMed Central
434 PMCID: PMCPMC9286920. 434 PMCID: PMCPMC9286920.
435 19. Riley RD, Snell KI, E 435 19. Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE, Jr., Moons KG, et al. Minimum sample 436 size for developing a multivariable prediction model: PART II - binary and time-to-event 436 size for developing a multivariable prediction model: PART II - binary and time-to-event
437 outcomes. Stat Med. 2019;38(7):1276-96. Epub 2018/10/26. doi: 10.1002/sim.7992. Pu 437 outcomes. Stat Med. 2019;38(7):1276-96. Epub 2018/10/26. doi: 10.1002/sim.7992. PubMed
438 PMID: 30357870: PubMed Central PMCID: PMCPMC6519266. 438 PMID: 30357870; PubMed Central PMCID: PMCPMC6519266.
439 20. Riley RD, Pate A, Dhiman P, Archer L, Martin GP, Collins 439 20. Riley RD, Pate A, Dhiman P, Archer L, Martin GP, Collins GS. Clinical prediction models 440 and the multiverse of madness. BMC Med. 2023;21(1):502. Epub 2023/12/19. doi: 440 and the multiverse of madness. BMC Med. 2023;21(1):502. Epub 2023/12/19. doi:
441 10.1186/s12916-023-03212-y. PubMed PMID: 38110939; PubMed Central PMCID: 441 10.1186/s12916-023-03212-y. PubMed PMID: 38110939; PubMed Central PMCID:
442 PMCPMC10729337. 442 PMCPMC10729337.
443 21. Pouresmaeili 443 21. Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview
444 on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029-49. Epub 2018/11/23 444 on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029-49. Epub 2018/11/23.
445 doi: 10.2147/tcrm.S138000. PubMed PMID: 30464484; PubMed Central PMCID: 445 doi: 10.2147/tcrm.S138000. PubMed PMID: 30464484; PubMed Central PMCID: 446 PMCPMC6225907. 446 PMCPMC6225907.
447 22. Chowdhurv M 447 22. Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical
448 prediction modelling. Fam Med Community Health. 2020;8(1):e000262. Epub 2020/03/10. do 448 prediction modelling. Fam Med Community Health. 2020;8(1):e000262. Epub 2020/03/10. doi:
449 10.1136/fmch-2019-000262. PubMed PMID: 32148735: PubMed Central PMCID: 449 10.1136/fmch-2019-000262. PubMed PMID: 32148735; PubMed Central PMCID:
450 PMCPMC7032893. 450 PMCPMC7032893.
451 23. Alba AC, Ago 451 23. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination
452 and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. Jama. 452 and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. Jama.
453 2017;318(14):1377-84. Epub 2017/10/20. doi: 10.1001/jama.2017.12126. PubMed PMID: 453 2017;318(14):1377-84. Epub 2017/10/20. doi: 10.1001/jama.2017.12126. PubMed PMID:
454 29049590. 454 29049590.
455 24. Kar 24. Kanis JA. Assessment of fracture risk and its application to screening for
456 postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. O 456 postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int.
457 1994;4(6):368-81. Epub 1994/11/01. doi: 10.1007/bf01622200. PubMed PMID: 7696835. 457 1994;4(6):368-81. Epub 1994/11/01. doi: 10.1007/bf01622200. PubMed PMID: 7696835.
458 25. Rubin KH, Holmberg T, Rothmann MJ, Høiberg M, Barkmann R, Gram J, et al. Th 458 25. Rubin KH, Holmberg T, Rothmann MJ, Høiberg M, Barkmann R, Gram J, et al. The risk-
459 stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-459 stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-
460 based study. Design and baseline characteristics. Calcif Tissue Int. 2015:96(2):167-79. Epub 460 based study. Design and baseline characteristics. Calcif Tissue Int. 2015;96(2):167-79. Epub 461 2015/01/13. doi: 10.1007/s00223-014-9950-8. PubMed PMID: 25578146. ⁴⁶¹2015/01/13. doi: 10.1007/s00223-014-9950-8. PubMed PMID: 25578146. 462 26. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of 463 osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 463 osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int.
464 2001;12(12):989-95. Epub 2002/02/16. doi: 10.1007/s001980170006. PubMed PMII ⁴⁶⁴2001;12(12):989-95. Epub 2002/02/16. doi: 10.1007/s001980170006. PubMed PMID: 465 11846333.
466 27. Kar 466 27. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International
467 Variations in Hip Fracture Probabilities: Implications for Risk Assessment. Journal of Bo 467 Variations in Hip Fracture Probabilities: Implications for Risk Assessment. Journal of Bone and 468 Mineral Research. 2002;17(7):1237-44. doi: https://doi.org/10.1359/jbmr.2002.17.7.1237. 468 Mineral Research. 2002;17(7):1237-44. doi: https://doi.org/10.1359/jbmr.2002.17.7.1237.
469 28. Feeratakulpisarn N. Charoensri S. Theerakulpisut D. Pongchaiyakul C. FRAX scor 469 28. Teeratakulpisarn N, Charoensri S, Theerakulpisut D, Pongchaiyakul C. FRAX score with 470 and without bone mineral density: a comparison and factors affecting the discordance in 470 and without bone mineral density: a comparison and factors affecting the discordance in
471 osteoporosis treatment in Thais. Arch Osteoporos. 2021;16(1):44. Epub 2021/02/27. doi: 471 osteoporosis treatment in Thais. Arch Osteoporos. 2021;16(1):44. Epub 2021/02/27. doi:
472 10.1007/s11657-021-00911-y. PubMed PMID: 33635451. 472 10.1007/s11657-021-00911-y. PubMed PMID: 33635451.
473 29. Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwar 473 29. Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, et al. A simple tool to
474 identify asian women at increased risk of osteoporosis. Osteoporos Int. 2001;12(8):699-705. 474 identify asian women at increased risk of osteoporosis. Osteoporos Int. 2001;12(8):699-705.
475 Epub 2001/10/03. doi: 10.1007/s001980170070. PubMed PMID: 11580084. 475 Epub 2001/10/03. doi: 10.1007/s001980170070. PubMed PMID: 11580084.
476 30. Chaovisitsaree S. Namwongprom SN, Morakote N, Suntornlimsiri N, 476 30. Chaovisitsaree S, Namwongprom SN, Morakote N, Suntornlimsiri N, Piyamongkol W.
477 Comparison of osteoporosis self assessment tool for Asian (OSTA) and standard assessment 477 Comparison of osteoporosis self assessment tool for Asian (OSTA) and standard assessment in
478 Menopause Clinic, Chiang Mai. J Med Assoc Thai. 2007;90(3):420-5. Epub 2007/04/13. 478 Menopause Clinic, Chiang Mai. J Med Assoc Thai. 2007;90(3):420-5. Epub 2007/04/13.
479 PubMed PMID: 17427514.

⁴⁷⁹PubMed PMID: 17427514.

- 480 31. Geater S, Leelawattana R, Geater A. Validation of the OSTA index for discriminating
481 between high and low probability of femoral neck and lumbar spine osteoporosis among Tha
-
- 481 between high and low probability of femoral neck and lumbar spine osteoporosis among Thai
482 postmenopausal women. J Med Assoc Thai. 2004;87(11):1286-92. Epub 2005/04/14. PubMec 482 postmenopausal women. J Med Assoc Thai. 2004;87(11):1286-92. Epub 2005/04/14. PubMed
483 PMID: 15825701.
- 483 PMID: 15825701.
484 32. Chen CC.
- 484 32. Chen CC, Rau CS, Wu SC, Kuo PJ, Chen YC, Hsieh HY, et al. Association of 485 Csteoporosis Self-Assessment Tool for Asians (OSTA) Score with Clinical Presentation
- 485 Osteoporosis Self-Assessment Tool for Asians (OSTA) Score with Clinical Presentation and
486 Expenditure in Hospitalized Trauma Patients with Femoral Fractures. Int J Environ Res Publ
- 486 Expenditure in Hospitalized Trauma Patients with Femoral Fractures. Int J Environ Res Public
487 Health. 2016;13(10). Epub 2016/10/14. doi: 10.3390/ijerph13100995. PubMed PMID: 487 Health. 2016;13(10). Epub 2016/10/14. doi: 10.3390/ijerph13100995. PubMed PMID:
488 27735874; PubMed Central PMCID: PMCPMC5086734.
-
- 488 27735874; PubMed Central PMCID: PMCPMC5086734.
489 33. Panichyawat N, Tanmahasamut P. Comparison of 489 33. Panichyawat N, Tanmahasamut P. Comparison of OSTA index and KKOS scoring
490 system for prediction of osteoporosis in postmenopausal women who attended Sirirai
-
- 490 system for prediction of osteoporosis in postmenopausal women who attended Siriraj
491 Menopause Clinic. J Med Assoc Thai. 2012;95(11):1365-71. Epub 2012/12/21. PubMe 491 Menopause Clinic. J Med Assoc Thai. 2012;95(11):1365-71. Epub 2012/12/21. PubMed PMID:
492 23252200.
- 492 23252200.
493 34. Ong 493 34. Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, Piaseu N, Teerarungsikul K, Sirisriro
494 R. et al. Prediction of low bone mineral density in postmenopausal women by artificial neural
- 494 R, et al. Prediction of low bone mineral density in postmenopausal women by artificial neural
495 network model compared to logistic regression model. J Med Assoc Thai. 1997;80(8):508-15.
- 495 network model compared to logistic regression model. J Med Assoc Thai. 1997;80(8):508-15.
496 Epub 1997/08/01. PubMed PMID: 9277083.
- ⁴⁹⁶Epub 1997/08/01. PubMed PMID: 9277083.

497

Area under ROC curve = 0.7792

